Opis działalności
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Zarząd & Rada nadzorcza
| CEO |
| Tim Van Hauwermeiren |
| Zarząd |
| Karen Massey, Karl Gubitz, Peter Ulrichts, Malini Moorthy, Luc Truyen, Arjen Lemmen, Andria Wilk, Marc Schorpion, Beth DelGiacco, Filip Borgions |
| Rada nadzorcza |
| Peter Verhaeghe, Don deBethizy, Pamela M. Klein, A.A. Rosenberg, James M. Daly, Camilla Sylvest, Ana Cespedes, Steve Krognes, Tim Van Hauwermeiren |
Dane firmy
| Nazwa: |
argenx SE |
| Adres: |
Laarderhoogtweg 25,NL-1101 EB Amsterdam |
| Telefon: |
- |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
https://www.argenx.com/ |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
- |
| Data IPO: |
07.10.2014 |
Relacje inwestorskie
| Nazwa: |
Beth DelGiacco |
| Telefon: |
+31 (0) 763 030 488 |
| Fax: |
- |
| E-mail: |
bdelgiacco@argenx.com
|
